GT
VKTX icon

Glenmede Trust’s Viking Therapeutics VKTX Stock Holding History

Glenmede Trust’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,028
Closed -$214K – 1431
2024
Q2 		$214K Sell
4,028
-3,021
-43% -$198K ﹤0.01% 1175
2024
Q1 		$578K Buy
+7,049
New +$314K ﹤0.01% 879
2023
Q3 		– Sell
-25,033
Closed -$417K – 1367
2023
Q2 		$417K Hold
25,033
– – ﹤0.01% 882
2023
Q1 		$417K Sell
25,033
-256
-1% -$2.64K ﹤0.01% 887
2022
Q4 		$238K Buy
+25,289
New +$113K ﹤0.01% 1047

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Glenmede Trust's VKTX Position: Q3 2024 in Review

Glenmede Trust sold out of Viking Therapeutics (VKTX) in Q3 2024, closing a stake of 4,028 shares — an estimated $214K sold.

Glenmede Trust first reported a position in VKTX in Q4 2022 and held it in 5 quarters. The position peaked at $578K in Q1 2024. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

  • Glenmede Trust reported no remaining Viking Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Glenmede Trust sold 4,028 Viking Therapeutics shares in Q3 2024, an estimated $214K.
  • Glenmede Trust first reported a position in Viking Therapeutics in Q4 2022 and held it in 5 quarters.
  • Glenmede Trust's Viking Therapeutics position peaked at $578K in Q1 2024.
  • 422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Glenmede Trust's 13F filing for Q3 2024, filed 13 Nov 2024.